A Potential New Option for Targeted Treatment of Pancreatic Cancer is on the Horizon
Systemic (intravenous) chemotherapy is currently considered to be the standard of care for pancreatic cancer treatment despite its often debilitating side effects for patients diagnosed with this disease. Unlike other tumors with extensive blood supply, pancreatic tumors lack the classical network of tumor-feeding blood vessels. Thus, the standard of care may be less effective in treating this type of cancer because the blood vessels are critical for transporting systemic administration of chemotherapy to the tumor.
The Phase III TIGeR-PaC clinical trial is a randomized multi-center study using RenovoRx’s innovative therapy platform, RenovoTAMP® (RenovoRx Trans-Arterial Micro-Perfusion), to evaluate RenovoRx’s first product candidate, RenovoGem™, for treatment of locally advanced pancreatic cancer (LAPC) through the intra-arterial delivery of gemcitabine (an FDA-approved chemotherapy). The study has a primary endpoint of overall survival and several secondary endpoints, including quality of life for patients diagnosed with LAPC.
Based on the results of the Phase I/II and observational registry studies, intra-arterial delivery of chemotherapy via RenovoTAMP, which targets delivery of treatment in proximity to the tumor and pancreatic tissue, reduced tolerability issues associated with systemic chemotherapy and demonstrated improved patient survival.
TIGeR-PaC is currently enrolling locally advanced, unresectable LAPC patients at multiple clinical centers across the U.S. Find a clinical site.